Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05720117 · ClinicalTrials.gov registry record · Phase 1

A Study of PYX-201 in Advanced Solid Tumors

A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Pyxis Oncology.

Recruiting
Registry status
Phase 1
Development phase
330
Enrollment target
20
Study locations

NCT05720117 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by Pyxis Oncology. The registered enrollment target is 330 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05720117, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by Pyxis Oncology.

RECRUITING
Registry status
Phase 1
Development phase
330 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

Conditions Studied

Solid Tumor Advanced Solid Tumor

Interventions

  • DRUG PYX-201

Study Locations (20)

Texas

  • NEXT Dallas - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT San Antonio - San Antonio

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Brussels Capital

  • Institut Jules Bordet - Brussels
  • Cliniques Universitaires Saint-Luc - Brussels

Arizona

  • HonorHealth Research Institute - Scottsdale

California

  • Ronald Reagan UCLA Medical Center - Los Angeles

Colorado

  • SCRI - HealthOne Denver - Denver

Florida

  • SCRI - Florida Cancer Specialists - Sarasota

Georgia

  • Winship Cancer Institute, Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2023-03-14
Est. Completion 2027-05
Phase Phase 1

Sponsor

Pyxis Oncology

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05720117

The ClinicalTrials.gov registry entry for NCT05720117 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher). The listed sponsor is Pyxis Oncology, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PYX-201 is the first listed.

NCT05720117 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Texas, Massachusetts, Brussels Capital.

Frequently Asked Questions

What is clinical trial NCT05720117 about?

NCT05720117 is a clinical study titled "A Study of PYX-201 in Advanced Solid Tumors". The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

What is the current status of trial NCT05720117?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2023-03-14. Estimated completion is 2027-05.

What conditions does trial NCT05720117 study?

This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.

What interventions are being tested in trial NCT05720117?

The interventions under investigation include: PYX-201 (DRUG).

Who is sponsoring clinical trial NCT05720117?

This trial is sponsored by Pyxis Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05720117 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.